Home Cart Sign in  
Chemical Structure| 195987-41-8 Chemical Structure| 195987-41-8

Structure of BMS-214662
CAS No.: 195987-41-8

Chemical Structure| 195987-41-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BMS-214662 is a potent and selective farnesyl transferase inhibitor with potent antitumor activity with an IC50 of 1.35 nM.

Synonyms: BMS-214662

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BMS-214662

CAS No. :195987-41-8
Formula : C25H23N5O2S2
M.W : 489.61
SMILES Code : C([C@H]1N(S(=O)(=O)C2=CC=CS2)CC=3C(N(CC4=CN=CN4)C1)=CC=C(C#N)C3)C5=CC=CC=C5
Synonyms :
BMS-214662
MDL No. :MFCD09955166

Safety of BMS-214662

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00004877 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00022529 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Pennsylvania ... More >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111-2497 Less <<
NCT00005973 Unspecified Adult Solid Tumor,... More >> Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00006018 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Ohio ... More >> Ireland Cancer Center at University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106-5065 Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210-1240 Less <<
NCT00006242 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT00006213 Adult Acute Promyelocytic Leuk... More >>emia (M3) Blastic Phase Chronic Myelogenous Leukemia Childhood Myelodysplastic Syndromes Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Anemia With Excess Blasts Refractory Anemia With Excess Blasts in Transformation Relapsing Chronic Myelogenous Leukemia Less << Phase 1 Completed - United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.21mL

2.04mL

1.02mL

20.42mL

4.08mL

2.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories